Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor.
Francesco SpinelliLinjing MuSimon M AmetameyPublished in: Journal of labelled compounds & radiopharmaceuticals (2017)
The cannabinoid type 2 (CB2) receptor is an immunomodulatory receptor mainly expressed in peripheral cells and organs of the immune system. The expression level of CB2 in the central nervous system under physiological conditions is negligible, however under neuroinflammatory conditions an upregulation of CB2 protein or mRNA mainly colocalized with activated microglial cells has been reported. Consequently, CB2 agonists have been confirmed to play a role in neuroprotective and anti-inflammatory processes. A suitable positron emission tomography radioligand for imaging CB2 would provide an invaluable research tool to explore the role of CB2 receptor expression in inflammatory disorders. In this review, we provide a summary of so far published CB2 radioligands as well as their in vitro and in vivo binding characteristics.
Keyphrases
- positron emission tomography
- computed tomography
- binding protein
- induced apoptosis
- high resolution
- poor prognosis
- pet ct
- pet imaging
- cell cycle arrest
- anti inflammatory
- oxidative stress
- inflammatory response
- signaling pathway
- cell proliferation
- systematic review
- cell death
- blood brain barrier
- spinal cord injury
- lps induced
- cerebrospinal fluid
- neuropathic pain
- brain injury
- pi k akt